HC Wainwright Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $51.00

AnaptysBio (NASDAQ:ANAB) had its target price reduced by HC Wainwright from $52.00 to $51.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for AnaptysBio’s Q4 2025 earnings at $1.67 EPS, FY2025 earnings at ($0.60) EPS, Q1 2026 earnings at ($1.02) EPS, Q2 2026 earnings at ($1.17) EPS, Q3 2026 earnings at ($1.62) EPS, Q4 2026 earnings at ($2.24) EPS, FY2026 earnings at ($6.31) EPS, FY2027 earnings at ($9.06) EPS, FY2028 earnings at ($4.42) EPS and FY2029 earnings at ($2.08) EPS.

Other research analysts have also issued research reports about the stock. Guggenheim lifted their price target on shares of AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a report on Monday, November 10th. Stifel Nicolaus upped their target price on shares of AnaptysBio from $55.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. UBS Group reiterated a “neutral” rating and set a $20.00 target price (up previously from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $59.30.

AnaptysBio Price Performance

Shares of AnaptysBio stock opened at $42.16 on Monday. The company has a market capitalization of $1.17 billion, a P/E ratio of -14.95 and a beta of 0.16. The business has a 50-day moving average of $32.81 and a two-hundred day moving average of $26.17. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $43.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The business had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $15.83 million. On average, equities analysts anticipate that AnaptysBio will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has approved a share buyback program on Friday, November 21st that allows the company to buyback $100.00 million in shares. This buyback authorization allows the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Light Asset Management LLC raised its holdings in AnaptysBio by 433.3% during the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock worth $86,139,000 after acquiring an additional 3,764,720 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares during the last quarter. Caption Management LLC raised its stake in shares of AnaptysBio by 106.3% during the 1st quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company’s stock worth $435,000 after purchasing an additional 394,634 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of AnaptysBio by 63.1% in the 1st quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after buying an additional 305,950 shares during the last quarter. Finally, 683 Capital Management LLC boosted its holdings in shares of AnaptysBio by 155.6% in the 2nd quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after buying an additional 304,373 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.